Actin-binding protein filamin A (FLNA) regulates signal transduction important for cell locomotion, but the role of FLNA after myocardial infarction (MI) has not been explored. The main purpose of this study was to determine the impact of endothelial deletion of FLNA on post-MI remodelling of the left ventricle (LV).
Introduction
After myocardial infarction (MI), the left ventricle (LV) undergoes molecular, cellular, and microcirculatory changes that dramatically alter the size, shape, and function at the organ level. Recent advances in our understanding of the control mechanisms regulating the development of new blood vessels in coronary heart disease have led to a better understanding of this essential compensatory healing process that accompanies myocardial ischaemia and infarction. 1 Angiogenesis executed by vascular endothelial cells (ECs) has the potential to salvage the ischaemic myocardium at early stages after MI and is also essential to prevent the transition to heart failure through the control of cardiomyocyte hypertrophy and contractility. Pro-angiogenic therapy has long been considered a promising strategy for the treatment of patients with acute MI. Despite the tremendous efforts on hypoxia-stimulated angiogenesis, an established curative treatment is lacking. Therefore, a comprehensive understanding of the endothelial responses in angiogenesis and identification of new molecules targeting the vascular endothelium are essential in developing therapies to prevent and treat MI.
Filamins are a family of cytoskeletal proteins that have been implicated as critical mediators of organ development and cell signalling and migration. 2 FLNA, a major isoform of the filamin family, is ubiquitously expressed and is indispensable for normal development. Null mutations in FLNA have been reported to cause brain malformations known as periventricular nodular heterotopia accompanied by high cardiovascular abnormalities including patent ductus arteriosus, aortic aneurysms, premature strokes, and minor cardiovascular abnormalities in humans who † These authors contributed equally to this work. die prenatally. 3 In mice, loss of Flna is associated with embryonic lethality caused by cardiac defects in the formation of ventricles, atria, and outflow tracts. The evident outcome of FLNA deficiency on structural defects in the blood vessels and heart suggests that FLNA plays a key role in cardiovascular morphogenesis. 4 Although expression of FLNA has previously been reported in vessels and in cultured ECs, 5 the endothelial significance of FLNA expression has not been determined. Besides, no data on the expression of FLNA have been reported in a remodelling myocardium in response to MI.
To study the role of FLNA in vascular ECs during cardiovascular remodelling, we used mice that are deficient for FLNA in ECs and induced MI by ligation of the left descending coronary artery. Using this mouse model, we demonstrate that infarcted hearts lacking FLNA in ECs exhibit impaired cardiac function and developed severe cardiac failure. In addition, we show a key role of FLNA in EC tube formation and motility, exerted through its function as an interacting protein affecting signalling proteins.
Methods

Mice
All mice included in this study had a C57Bl/6 genetic background. Female mice 6 expressing Flna fl/fl were cross-bred with transgenic male mice expressing Cre under the control of the EC-specific VE-Cadherin promoter (VECadCre+, The Jackson Laboratory, Bar Harbor, ME 
Immunostaining
Paraffin-embedded infarcted human and mouse hearts were sectioned and immunohistochemically stained with an antibody against FLNA (Chemicon International), FLNB (Chemicon), and FLNC (Kinasource) as described previously. 8 Antibodies directed against CD31 (Thermo Scientific) and Ki67
(Thermo Scientific) were used to detect cardiac ECs and replicating cells, respectively, as described earlier. 7 For IF, secondary FITC-conjugated and Alexa conjugated antibodies (Molecular Probes, Sweden) were used. Images were captured using Leica Microsystems microscope. Number of CD31-positive structures in infarcted (entire area) and non-infarcted areas (5 randomly areas) was counted in at least seven mice in each group.
Echocardiography
Echocardiography was performed under anaesthesia by inhalation of 1.5-2% isoflurane (Forene isoflurane, Abbott Scandinavia AB, Sweden) as described earlier. 7 Images were acquired using the Vevo660 system (Visual Sonics) with a 30 MHz linear transducer. The left ventricle was investigated in both long-axis and short-axis views 25 weeks after MI. Estimated ejection fraction (EF), an index of the cardiac systolic function was calculated as EF ¼ [(EDA 2 ESA)/EDA] × 100, where EDA and ESA representing enddiastolic and end-systolic LV luminal areas, respectively, measured in high-resolution parasternal short-axis EKV acquired cine loops (1000 Hz) at the level of the papillary muscles and LV apex. For the stress test, dobutamine (1 mg/g mouse weight, Sigma Chemicals) was injected intraperitoneally. Short-axis cine loops at the papillary plane were stored at baseline, 5, and 10 min post dobutamine, and EF was calculated. Offline measurements were performed using the manufacturer's software (V3.0.0, Vevo770, Visual Sonics). 
Isolation and culture of ECs
Mice were killed under inhalation of 5% isoflurane, and mouse death was confirmed by dissecting hearts. Primary cardiac ECs were isolated using rat anti-ICAM2 (BD PharMingen) antibody-coated magnetic beads (Dynabeads M-450, sheep anti-Rat IgG, Dynal) from whole mouse hearts as described earlier. 6 The transformed pancreatic endothelial MS1 cell line (ATCC) was cultured as described earlier. 9 Human umbilical vein ECs (HUVECs) were cultured in basal medium supplemented with growth factors (EBM-2 bullet kit LONZA) as described earlier. 
Migration assay
Migration assay was performed on primary cardiac and MS1 ECs. Cell migration was quantified with a modified Boyden chamber assay where the ability of cells to migrate through a microporous nitrocellulose filter (8 mm thick, 8 mm pores in diameter) was measured as described earlier. 6 Triplicates of each sample are presented as mean + SD values.
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Phalloidin staining
In triplicated independent experiments, MS1 cells transfected with either negative control (ø) or Flna siRNA were incubated in 4-well chamber slides for 24 h at 378C with 5% CO 2 . The cells were fixed with 4% paraformaldehyde for 30 min at room temperature (RT), permeabilized for 30 min with PBST plus 0.01% Triton X-100 for 30 min, and stained with Phalloidin (Invitrogen) for 1 h at RT followed by three wash steps for 10 min. Pictures were taken from five optical fields (×20) on each well, and cell shape was analysed. In at least seven high-power fields consisting of at least 150 MS1 cells, the ratio of length between cellular long and short axis was quantified.
Tube formation assay
HUVEC cells were transfected with either negative siRNA or siRNA Flna 2 days before tube formation assay. Forty-eight-well plates were coated with growth factor-reduced Matrigel 50 mL/cm 2 following the manufacturer's instructions (BD Biosciences). After trypsinization, HUVECs were centrifuged; 1 × 10 4 cells were re-suspended in 250 mL complete DMEM containing 10% fetal bovine serum and seeded in each well. Cells were cultured in a 5% CO 2 incubator overnight. Five images were taken from each well by using an inverted microscope (×40). Tube length was quantified by using ImageJ software.
Immunoblotting and RAC-1 activity
Cell lysates were assayed by immunoblotting as described earlier. 6 Primary
, and actin (Sigma Aldrich) were used. The band densities of triplicated independent experiments were quantified by ImageQuant software (Bio-Rad). GTP-bound RAC1 was affinity precipitated with PAK1-GST (Rac1 Activation Kit; Pierce) following the manufacturer's instructions and was immunoblotted using antibody supplied in the kit (Millipore).
Quantitative PCR
mRNA was isolated using the RNeasy Mini Kit (Qiagen), and cDNA was synthesized with High Capacity cDNA Reverse Transcription Kit (Applied Biosystems) according to the protocol provided by the manufacturer. Gene expression was analysed using TaqMan assays with mouse probes for Flna (Mm01187533_m1), Flnb (Mm01311723_m1), Flnc (Mm00471824_ m1), and Hprt (Mm01545399_m1).
Statistics
All the values are mean + SD, and the differences between groups were evaluated with a two-tailed Student's t-test or one-way ANOVA. The survival rates between groups were plotted by the Kaplan -Meier X 2 test. A P-value of ,0.05 was considered significant.
Results
FLNA is expressed by ECs in infarcted human and mouse hearts
To detect whether FLNA is expressed in infarcted hearts, we stained human biopsies of MI for FLNA. FLNA was expressed by infarcted human cardiac tissues. Particularly, endothelial structures in these tissues expressed FLNA as detected by double labelling of FLNA and CD31 ( Figure 1A ). The FLNA staining in infarcted mouse hearts is consistent with human biopsies as microvascular structures were positively stained for FLNA ( Figure 1B) . In addition to ECs, cardiac myocytes, vascular smooth muscle cells, and fibroblasts also expressed FLNA in heart sections (Supplementary material online, Figure S1A ).
Deficiency of endothelial FLNA leads to enlargement and thinning of the cardiac wall following MI
To produce mice that are deficient for endothelial FLNA, we cross-bred female Flna fl/fl mice with transgenic male mice expressing Cre under control of EC-specific VE-Cadherin promoter (VECadCre+) as reported earlier. 6 Their male offspring with Cre expression and thus lacking FLNA specifically in ECs are designated as Flna o/fl /VECadCre+. Mice that are Endothelial filamin A impacts cardiac remodelling deficient for endothelial FLNA survived normally and exhibited no cardiovascular malformation and no impairment in cardiac pump function and histomorphology at the basal level. 6 To verify that ECs lack expression of FLNA, we extracted primary cardiac ECs and immunoblotted cell lysates for FLNA expression ( Figure 2A ). Our data indicated that FLNA is remarkably deleted in the ECs of Flna o/fl /VECadCre+ hearts. These ECs also expressed FLNB and FLNC; however, no compensatory increase in the expression of either FLNB or FLNC was observed at the protein level in the FLNA-deficient ECs (Supplementary material online, Figure  S1B and C). To determine whether endothelial expression of FLNA has a biological importance during cardiac remodelling, we induced MI by permanent ligation of the left coronary descending artery as described earlier 8 and removed hearts for analysis 25 weeks after MI. 
Impaired cardiac function in infarcted hearts lacking endothelial FLNA
To determine whether morphological changes in hearts lead to consequences in cardiac function, we performed echocardiography at both the papillary and apex plane 25 weeks after MI ( Figure 3A and B) . We further stressed hearts by intraperitoneal injection of dobutamine and collected images at the papillary level after 5 and 10 min ( /VECadCre+ hearts lacked this response (28.5 + 11.5 vs. 21.1 + 11.5%, P ¼ 0.18) ( Figure 3C ).
Increased infarction size and decreased capillarity in hearts lacking endothelial FLNA
Following echocardiography, hearts were removed for histological studies. To quantify infarction scar size, cardiac sections were stained with Masson's trichrome at six different levels ( Figure 4A Endothelial filamin A impacts cardiac remodelling panel). As blood vessel remodelling is crucial for myocardial healing after MI and Flna deficiency results in impaired tumour capillarity, 6 we assessed capillary structures of these hearts by immunohistochemistry with CD31 antibody ( Figure 4B, left 
Absence of FLNA impairs endothelial tube formation and migration
The reduced capillarity in Flna o/fl /VECadCre+ hearts is likely caused by compromised angiogenesis of Flna-deficient ECs. To measure the ability of ECs to form capillary-like structures, we performed a tube formation assay using HUVEC in Matrigel. The efficient knockdown of Flna in HUVEC (Supplementary material online, Figure S2 ) displayed significantly reduced tube length compared with control cells (203 + 3.21 vs. 134 + 1.61 mm, P , 0.01) ( Figure 5A ). The shortened tube length can be caused by impaired EC migration as a result of Flna deficiency as reported earlier in tumours. 6 We therefore tested this hypothesis both on primary cardiac ECs deficient for FLNA ( Figure 5B ) and on Flna knockdown MS1 ECs ( Figure 5C ), and observed a significant reduction in cell migration by 19% (P , 0.05) and 29% (P , 0.01), respectively. In addition, non-silenced and Flna knockdown MS1 cells displayed different morphology in vitro. Non-silenced MS1 cells were characterized by an elongated morphology with apparent ventral stress fibres, while Flna knockdown MS1 cells displayed more round shape ( Figure 5D , left panels). The ratio of length between long and short axis of Flna knockdown MS1 ECs was dropped significantly (from 3.2 + 0.6-to 2.4 + 0.4-folds, P , 0.01, Figure 5D , right panel).
Lack of FLNA compromises endothelial signalling
To determine the molecular mechanisms behind the decreased tubular formation and cell migration, we studied the expression of signalling molecules p-AKT, p-ERK1/2, and RAC-1 that are essential for cell migration and angiogenesis ( Figure 6A ). These studies indicated reduced levels of p-AKT (by 54%, P , 0.001, Figure 6B ), p-ERK1/2 (by 19%, P , 0.05, Figure 6C ), and RAC-1 (by 52%, P , 0.05, Figure 6D ) in ECs transfected with shRNA Flna compared with cells transfected with control shRNA Ø. Consistent with MS1 ECs, Flna knockdown HUVEC also displayed significantly reduced p-AKT (Supplementary material online, Figure S2 ). Importantly, the RAC-1 activity was decreased by 51% in MS1 ECs transfected with shRNA Flna (P , 0.05, Figure 6E ). VEGF-A is one of the activators of AKT/ERK/RAC-1 signalling pathway. We found a decrease in the level of secreted VEGF-A from cultured MS1 ECs after Flna silencing (217.5 + 23.2 vs. 108.0 + 7.0 pg/mL, P , 0.01, Figure 6F ). Consistent with this finding, Flna o/fl /VECadCre+ mice also produced significantly lower level of secreted VEGF-A in the circulating blood compared with Flna o/fl mice (12.1 + 2.5 vs. 17.1 + 0.7 pg/mL, P ¼ 0.05, Figure 6G ) after MI.
Discussion
This study evaluated the impact of endothelial FLNA deletion on MI-induced LV remodelling and dysfunction, focusing on the EC function and signalling. The major findings are as follows: (i) FLNA is expressed by myocardial ECs after MI; (ii) endothelial deletion of FLNA leads to impaired LV remodelling and dysfunction, accompanied by increased MI size, thinning of LV wall, and enlargement of LV lumen; (iii) FLNA deficiency in ECs leads to reduced capillarity in infarcted hearts; and (iv) EC signalling is impaired by the absence of FLNA, resulting in reduced EC tube formation and migration. Taken together, these findings demonstrate that FLNA deficiency in vascular ECs aggravates post-MI remodelling and cardiac dysfunction by impairing EC signalling and migration. Importantly, this study deepens our understanding of FLNA function in EC biology and cardiovascular diseases, in addition to our preconceived idea that FLNA primarily plays structural roles in the cytoplasm.
Recently, an increasing number of reports indicates that cardiovascular defects are associated with the loss of FLNA function in humans. 3 The X-linked form of hereditary cardiac valvular dystrophy and cardiac valve disease are linked to mutations in the FLNA gene. 10 FLNA is highly expressed in ECs, the endocardial cushion, and mesenchymal cells.
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Furthermore, deficiency of Flna in mice results in severe malformations in the heart and blood vessels, suggesting that FLNA affects the development of the endocardial cushion which is essential for cardiovascular morphogenesis. 4 All these previous findings point to a potential role of endothelial FLNA in cardiovascular development. Surprisingly, our mice lacking FLNA specifically in ECs grow normally and their cardiac functions appear to be normal. 6 Thus, we questioned whether endothelial FLNA could play a role in cardiovascular diseases such as MI when the demand for cellular signalling mediated by FLNA is increased. As we have shown, FLNA is expressed in the infarcted area after MI, while its consequence on myocardial remodelling and function has not been explored. In this study, we found that endothelial deletion of FLNA led to worsened histomorphological and functional properties in infarcted hearts. In addition, mice that are deficient for endothelial FLNA had no response to dobutamine stress, indicating that the cardiac motility reserve is compromised in these mice. Finally, the elevated NT-proBNP levels in mice lacking endothelial FLNA indicated exacerbated MI-induced LV failure. Therefore, deletion of endothelial FLNA alone is not sufficient to retard heart development, whereas in MI, if expression of endothelial FLNA is not present, aberrant myocardial remodelling and heart dysfunction occur. Due to the limited regenerative capacity of the mammalian myocardium, a proper angiogenic response is required to repair the substantial loss of cardiomyocytes during MI, both to provide nutrients and to maintain normal blood vessel wall function. Thus, fully functional ECs are of The ratio of length between long axis and short axis of cells was quantified (right graph, n ¼ 3). Scale bar shows 2.5 mm. Two-tailed Student's t-test, *P , 0.05 and **P , 0.01 vs. respective control groups.
Endothelial filamin A impacts cardiac remodelling great importance to form a new vasculature and to prevent progressive LV remodelling. Endothelial malfunction may partly contribute to the phenotype that accounts for the severe cardiac developmental defects in mice deficient for FLNA. 4 Moreover, in patients with multiple myeloma, FLNA is implicated in multiple endothelial angiogenesisrelated functions, including cell spreading, migration, and tubular morphogenesis. 12 We therefore tested whether endothelial FLNA could impact angiogenesis in infarcted hearts. Interestingly, the number of formed capillary structures was not altered in non-infarcted myocardium but was significantly reduced in infarcted areas in hearts lacking endothelial FLNA, which likely results in increased infarction size. These findings suggest that the pro-angiogenic function of FLNA is only induced under stressed conditions, which may explain the normal phenotype of mice lacking endothelial FLNA. In contrast, no difference in EC proliferation was observed between hearts expressing and lacking endothelial FLNA in this study, indicating that the reduced capillarity may be due to impaired migration of pre-existing ECs. In the heart, both the vasculature and interior surfaces of the chambers called endocardium are covered by ECs. Active migration of pre-existing ECs towards an ischaemic stimulus may precede cell proliferation during cardiac adaptive angiogenesis. FLNA has been implicated in both proliferation and migration processes, though the published results are controversial in various cell types. In our study, we found that FLNA does not regulate EC proliferation. Thus, the impaired angiogenesis observed in hearts lacking endothelial FLNA is likely mediated by reduced cell migration. In support of this hypothesis, we have earlier found that targeted deletion of FLNA in ECs leads to reduced migration and angiogenesis in cancer cells and thus tumour growth in mice. 6 In this study, we observed that both genetic deletion of FLNA in primary cardiac ECs and acute knockdown of FLNA expression in transformed ECs inhibit cell migration. Since ECs play a crucial role in the formation of blood vessels, decreased cell migration may result in poor angiogenesis in these mouse hearts that are stressed with MI. The VEGF signalling pathway plays an essential role in the initiation and regulation of angiogenesis during MI. 13 Interestingly, we have recently shown that the naturally occurring C-terminal fragment of FLNA interacts with HIF-1a in tumour cells. 14 As a consequence of this interaction, secretion of VEGF-A is up-regulated during hypoxia. HIF-1a and VEGF are also up-regulated during MI and regulate hypoxia-stimulated angiogenesis. 15, 16 Importantly, we showed in this study that mice with infarcted hearts lacking endothelial FLNA secrete less VEGF-A. VEGF-A can readily bind to its plasma membrane receptor VEGFR-2 on ECs and activate its downstream pathways, including the AKT, ERK, and small GTPase RAC-1 signalling pathways. 17 Our immunoblotting data confirmed a decrease in the level of active RAC-1 and phosphorylated AKT and ERK in ECs lacking FLNA, indicating that impaired VEGF-A production may at least be one cause of the reduced migration in these cells. The differential morphology between non-silenced and Flna knockdown ECs were reminiscent of FLNA-expressing and -lacking melanoma cells, which may account for the differential migration capability. Thus, FLNA may regulate angiogenesis through either direct interaction with small GTPases or indirect regulation of VEGF-Asecretion that reciprocally activate MAPK signalling. FLNB, another filamin isoform, has been shown to regulate EC migration by interacting with RAC1. 18 Whereas FLNA has been shown to interact with small GTPases RhoA, Cdc42, and RAC-1 in other cell types, 2 its functional importance in ECs has not been studied. Our study provides the first evidence that FLNA-regulated RAC-1 signalling may be involved in angiogenesis in MI.
In conclusion, endothelial FLNA deletion aggravated post-MI LV dysfunction and cardiac failure by blunting the angiogenic responses that are necessary for proper wound healing. Therefore, inducing FLNA and associated pathways in the post-MI setting would likely provide a favourable approach to inhibit abnormal cardiac remodelling post-MI.
Supplementary material
Supplementary material is available at Cardiovascular Research online.
